Some of the latest aHUS, CM-TMA and TMA research being displayed at the American Society of Haematologists , ASH, conference 2024
Ravulizumab switch from eculizumab after 3 months
This is a study which includes Alexion authors and shows that improvement continues in key measures – platelets, LDH, creatinine – in a cohort of predominantly male, later onset patients. Full TMA response achieved in 18 months in around 70% of cohort.
A deeper dive into PNH aHUS and ITP
No information but a sponsored forum by Novartis.
Patient Reported Outcomes in long term aHUS patients
A study of long term experience of patient reported physical and emotional outcomes of 55 predominantly female (85%) and older USA patients. Most were still on complement inhibitor treatment and 1 in 4 had a kidney transplant. Results showed differences in key measures compared with the general population. Authors included two directors of aHUS alliance Global Action.
TTP is seen as the typical TMA and aHUS is regarded as one of the atypical TMAs, along with Transplant Associated and CAPs in this educational session for Haematologists.
TMAs – Clinical and epidemiology Poster
A symposia about a range of TMA abstracts ( Nos. 1236 to 1244) including the one about patient reported outcomes referred to above.
TMAs- Basic and Translational Poster
A second symposia about a ranges of abstracts ( Nos 2602 to 2613) including the one about ravulizumab switch mentioned above.
What’s new in complement mediated diseases
A poster walk through studies of complement being implicated in other forms of TMA.
Leveraging AI in diagnosing TMAs
An unusual study which looked at Artificial Intelligence GPT-4 use in potentially assisting differential diagnoses of TMAs. 98 case studies of TMAs including HUS with full information were found and key measures were entered to the A! instrument without the diagnosis. It was successful on identifying TTP but less so on other forms of TMA. Nothing new to aHUS patients perhaps.
Use of biosensors in classic and alternative pathway TMAs
This was a report on a new blood measure for complement mediated TMAs including aHUS. Global Action featured this research in an article earlier this year.
So that is a quick dip into what is going on at ASH for this year.
Article No. 702
